Akili Interactive Labs has raised $11.9m in an extension from Merck Group and Amgen, raising the round's total to $42.4m.
US-based digital medicine developer Akili Interactive Labs boosted its series B round to $42.4m on Wednesday following $11.9m of additional funds provided by pharmaceutical firms Amgen and Merck Group.
The corporates supplied the cash through their respective investment subsidiaries, Amgen Ventures and Merck Ventures, the latter of which operates as M Ventures in North America.
Akili received the initial $30.5m from healthcare R&D company PureTech Health, Jazz Venture Partners and Canepa Advanced Healthcare Fund in January 2016.
Akili develops…